In yesterday’s Wall Street session, Roivant Sciences Ltd (NASDAQ:ROIV) shares traded at $10.84, up 7.54% from the previous session.
ROIV stock price is now 1.10% away from the 50-day moving average and 2.82% away from the 200-day moving average. The market capitalization of the company currently stands at $8.74B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 96,950 shares of the company’s stock on Feb 09 ’24. The stock was sold for $1,058,694 at an average price of $10.92. Upon completion of the transaction, the President & COO now directly owns 532,207 shares in the company, valued at $5.77 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 02 ’24, 10% Owner Ramaswamy Vivek sold 3,000,000 shares of the business’s stock. A total of $33,150,000 was realized by selling the stock at an average price of $11.05. This leaves the insider owning 51,929,426 shares of the company worth $562.91 million. A total of 40.16% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $6.92 and a high of $13.24. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 27.79, and a quick ratio of 27.77. The fifty day moving average price for ROIV is $10.72 and a two-hundred day moving average price translates $10.55 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $6.03, beating analysts’ expectations of -$0.32 by 6.35. This compares to -$0.54 EPS in the same period last year. The net profit margin was 3624.14% and return on equity was 123.54% for ROIV. The company reported revenue of $37.14 million for the quarter, compared to $17.05 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 117.8 percent. For the current quarter, analysts expect ROIV to generate $33.28M in revenue.
